Acute lymphoblastic leukemia (ALL) is the commonest childhood tumor and remains a leading cause of cancer death in the young. In the last decade, microarray and sequencing analysis of large ALL cohorts has revolutionized our understanding of the genetic basis of this disease. These studies have identified new ALL subtypes, each characterized by constellations of structural and sequence alterations that perturb key cellular pathways, including lymphoid development, cell-cycle regulation, and tumor suppression; cytokine receptor, kinase, and Ras signaling; and chromatin modifications. Several of these pathways, particularly kinase-activating lesions and epigenetic alterations, are logical targets for new precision medicine therapies. Genomic profiling has also identified important interactions between inherited genetic variants that influence the risk of leukemia development and the somatic genetic alterations that are required to establish the leukemic clone. Moreover, sequential sequencing studies at diagnosis, remission, and relapse have provided important insights into the relationship among genetic variants, clonal heterogeneity, and the risk of relapse. Ongoing studies are extending our understanding of coding and noncoding genetic alterations in B-progenitor and T-lineage ALL and using these insights to inform the development of faithful experimental models to test the efficacy of new treatment approaches.

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer.1  Five-year survival rates now exceed 85% in children, but survival following relapse is poor.2  ALL comprises multiple entities with distinct genetic alterations, clinical features, and treatment response. Over the last decade, studies utilizing microarray analysis of gene expression, DNA copy-number alterations, and next-generation sequencing have provided major insights into the pathogenesis and clinical behavior of ALL.3-22  Most ALL genomes harbor sequence and structural DNA alterations involving coding genes, as well as alterations of noncoding elements such as noncoding RNAs23  and enhancer elements.24,25 

Here, we consider results from these studies in several categories: (1) identification of new subtypes of ALL that lack recurring gross chromosomal alterations; (2) characterization of the constellations of genetic alterations that define each ALL subtype; (3) the relationship between genetic alterations, clonal heterogeneity, and relapse; (4) identification of inherited genetic variants and mutations linked to ALL susceptibility and outcome; (5) and translating new discoveries to improved diagnostic, prognostic, and precision medicine approaches.

Gross chromosomal alterations are a hallmark of ALL (Table 1).26  High hyperdiploidy (>50 chromosomes) occurs in 25% to 30% of childhood B-cell precursor ALL (B-ALL) and is associated with favorable outcome. Hypodiploidy with <44 chromosomes is uncommon (2% to 3% of cases) and is associated with poor outcome.27,28 

Table 1

Key subtypes of ALL

SubtypePrevalence (%)*Comment
B-cell precursor ALL   
 Hyperdiploidy with >50 chromosomes 20-30 Excellent prognosis 
 Hypodiploidy with <44 chromosomes 2-3 Poor prognosis; high frequency of Ras pathway and Ikaros gene family mutations 
 t(12;21)(p13;q22) translocation encoding ETV6-RUNX1 15-25 Excellent prognosis 
 t(1;19)(q23;p13) translocation encoding TCF3-PBX1 2-6 Increased incidence in African-Americans; generally excellent prognosis; association with CNS relapse 
 t(9;22)(q34;q11.2) translocation encoding BCR-ABL1 2-4 Historically poor outcome; improved with addition of imatinib and/or dasatinib to intensive chemotherapy 
 Ph-like ALL 10-15 Multiple kinase-activating lesions; associated with older age, elevated white blood cell count, and IKZF1 alteration; potentially amenable to TKI therapy 
 t(4;11)(q21;q23) translocation encoding MLL-AF4 fusion 1-2 Common in infant ALL (especially age <6 mo); poor prognosis 
 t(8;14)(q24;q32), t(2;8)(q12;q24), t(2;8)(q12;q24) encoding; MYC rearrangement Favorable prognosis with short-term high-dose chemotherapy 
CRLF2 rearrangement (IGH-CRLF2; P2RY8-CRLF25-7 Common in Down syndrome–associated and Ph-like ALL (∼50% each); associated with IKZF1 deletion and/or mutation and JAK1/2 mutation and poor prognosis in non–Down syndrome–associated ALL 
ERG-dysregulated ALL ∼7 Distinct gene expression profile; the majority have focal ERG deletions and favorable outcome despite IKZF1 alterations 
PAX5 rearrangement ∼2 Multiple partners, commonly from dic(7;9), dic(9;12), and dic(9;20) 
 iAMP21 ∼2 Complex structural alterations of chromosome 21; rarely associated with a constitutional Robertsonian translocation rob(15;21)(q10;q10)c; poor prognosis 
T-lineage ALL 
 t(1;7)(p32;q35) and t(1;14)(p32;q11) translocations and interstitial 1p32 deletion; TAL1 dysregulation 15-18 Generally favorable outcome 
 t(11;14)(p15;q11) translocation and 5′ LMO2 deletion; LMO2 dysregulation 10 Generally favorable outcome 
 t(10;14)(q24;q11) and t(7;10)(q35;q24) translocations; TLX1 [HOX11] dysregulation Good prognosis 
 t(5;14)(q35;q32) translocation; TLX3 dysregulation 20 Commonly fused to BCL11B, also a target of deletion and/or mutation; poor prognosis 
 t(10;11)(p13;q14) translocation; PICALM-MLLT10 [CALM-AF10] 10 May have poor outcome 
MLL-MLLT1 [MLL-ENL] 2-3 Superior prognosis to other types of MLL-rearranged leukemia 
 9q34 amplification encoding NUP214-ABL1 Potentially amenable to TKIs, also identified in high-risk B-ALL; other kinase fusions identified in T-ALL include EML1-ABL1, ETV6-JAK2, and ETV6-ABL1 
 t(7;9)(q34;q34) translocation <1 Rearrangement of NOTCH1; also sequence mutations in >50% T-ALL 
Early T-cell precursor ALL 10-15 Immature immunophenotype; expression of myeloid and/or stem cell markers; historically poor outcome, although improved in recent studies; genetically heterogeneous with mutations in hematopoietic regulators, cytokine, and Ras signaling, and epigenetic modifiers 
SubtypePrevalence (%)*Comment
B-cell precursor ALL   
 Hyperdiploidy with >50 chromosomes 20-30 Excellent prognosis 
 Hypodiploidy with <44 chromosomes 2-3 Poor prognosis; high frequency of Ras pathway and Ikaros gene family mutations 
 t(12;21)(p13;q22) translocation encoding ETV6-RUNX1 15-25 Excellent prognosis 
 t(1;19)(q23;p13) translocation encoding TCF3-PBX1 2-6 Increased incidence in African-Americans; generally excellent prognosis; association with CNS relapse 
 t(9;22)(q34;q11.2) translocation encoding BCR-ABL1 2-4 Historically poor outcome; improved with addition of imatinib and/or dasatinib to intensive chemotherapy 
 Ph-like ALL 10-15 Multiple kinase-activating lesions; associated with older age, elevated white blood cell count, and IKZF1 alteration; potentially amenable to TKI therapy 
 t(4;11)(q21;q23) translocation encoding MLL-AF4 fusion 1-2 Common in infant ALL (especially age <6 mo); poor prognosis 
 t(8;14)(q24;q32), t(2;8)(q12;q24), t(2;8)(q12;q24) encoding; MYC rearrangement Favorable prognosis with short-term high-dose chemotherapy 
CRLF2 rearrangement (IGH-CRLF2; P2RY8-CRLF25-7 Common in Down syndrome–associated and Ph-like ALL (∼50% each); associated with IKZF1 deletion and/or mutation and JAK1/2 mutation and poor prognosis in non–Down syndrome–associated ALL 
ERG-dysregulated ALL ∼7 Distinct gene expression profile; the majority have focal ERG deletions and favorable outcome despite IKZF1 alterations 
PAX5 rearrangement ∼2 Multiple partners, commonly from dic(7;9), dic(9;12), and dic(9;20) 
 iAMP21 ∼2 Complex structural alterations of chromosome 21; rarely associated with a constitutional Robertsonian translocation rob(15;21)(q10;q10)c; poor prognosis 
T-lineage ALL 
 t(1;7)(p32;q35) and t(1;14)(p32;q11) translocations and interstitial 1p32 deletion; TAL1 dysregulation 15-18 Generally favorable outcome 
 t(11;14)(p15;q11) translocation and 5′ LMO2 deletion; LMO2 dysregulation 10 Generally favorable outcome 
 t(10;14)(q24;q11) and t(7;10)(q35;q24) translocations; TLX1 [HOX11] dysregulation Good prognosis 
 t(5;14)(q35;q32) translocation; TLX3 dysregulation 20 Commonly fused to BCL11B, also a target of deletion and/or mutation; poor prognosis 
 t(10;11)(p13;q14) translocation; PICALM-MLLT10 [CALM-AF10] 10 May have poor outcome 
MLL-MLLT1 [MLL-ENL] 2-3 Superior prognosis to other types of MLL-rearranged leukemia 
 9q34 amplification encoding NUP214-ABL1 Potentially amenable to TKIs, also identified in high-risk B-ALL; other kinase fusions identified in T-ALL include EML1-ABL1, ETV6-JAK2, and ETV6-ABL1 
 t(7;9)(q34;q34) translocation <1 Rearrangement of NOTCH1; also sequence mutations in >50% T-ALL 
Early T-cell precursor ALL 10-15 Immature immunophenotype; expression of myeloid and/or stem cell markers; historically poor outcome, although improved in recent studies; genetically heterogeneous with mutations in hematopoietic regulators, cytokine, and Ras signaling, and epigenetic modifiers 

CNS, central nervous system.

*

Frequencies refer to childhood ALL.

Chromosomal rearrangements creating chimeric fusion genes commonly involve hematopoietic transcription factors, epigenetic modifiers, cytokine receptors, and tyrosine kinases.26  Common rearrangements in B-lineage ALL are the t(12;21)(p13;q22) encoding ETV6-RUNX1 (TEL-AML1), t(1;19)(q23;p13) encoding TCF3-PBX1 (E2A-PBX1), t(9;22)(q34;q11.2) resulting in formation of the “Philadelphia” chromosome (Ph) encoding BCR-ABL1, rearrangements of MLL (KMT2A) at 11q23 to a range of fusion partners, and rearrangement of the cytokine receptor gene CRLF2 at the pseudoautosomal region 1 (PAR1) at Xp22.3/Yp11.3.6,29  Approximately 20% of childhood B-ALL cases lack one of these alterations and have alternative sentinel genetic lesions, including deregulation of the ETS-family transcription factor ERG, or one of a diverse range of alterations that drive kinase signaling in Ph-like ALL. T-ALL is characterized by activating mutations of NOTCH1 and rearrangements of transcription factors TLX1 (HOX11), TLX3 (HOX11L2), LYL1, TAL1, and MLL (Table 1).

The prevalence of these subtypes varies with age (Figure 1). High hyperdiploidy and ETV6-RUNX1 are each present in 25% to 30% of childhood ALL cases but occur in <3% of young adults (age 21-39 years). Conversely, BCR-ABL1–positive ALL comprises 2% to 5% of childhood vs one-quarter of adult ALL. Ph-like ALL rises in prevalence from 10% of children with standard-risk ALL to over 25% of young adults.7,22,30 

Figure 1

Prevalence of ALL subtypes across age groups. The prevalence of ALL subtypes varies between children with standard-risk ALL (age 1-9 years, white blood cell count <50 × 109/L), children with high-risk ALL (age 10-15 years and/or white blood cell count >50 × 109/L), adolescents (age 16-20 years), and young adults with ALL (age 21-39 years). B-other, B-cell ALL with other subtypes.

Figure 1

Prevalence of ALL subtypes across age groups. The prevalence of ALL subtypes varies between children with standard-risk ALL (age 1-9 years, white blood cell count <50 × 109/L), children with high-risk ALL (age 10-15 years and/or white blood cell count >50 × 109/L), adolescents (age 16-20 years), and young adults with ALL (age 21-39 years). B-other, B-cell ALL with other subtypes.

Close modal

Most ALL cases harbor multiple somatic genetic alterations in addition to gross chromosomal alterations (Table 2 and Figure 2).3,4,7  Chromosomal rearrangements and aneuploidy are early events in leukemogenesis, with DNA copy-number alterations and sequence mutations acquired subsequently. This is supported by several observations: (1) monochorionic twins concordant for an ALL chimeric fusion but discordant for secondary genetic alterations,31  (2) the universal presence of translocations or aneuploidy in ALL cells from a given patient or patient-derived xenograft but variability in submicroscopic genetic alterations,32,33  (3) genomic studies of matched diagnosis and relapse samples that typically show concordance for translocations in each patient at each time point but evolution in additional genetic changes,34  and (4) sequencing studies showing that many ALL cases harbor multiple subclonal sequence mutations in individual genes but constancy of chromosomal rearrangements.35 

Table 2

Key genetic alterations in ALL

GeneAlterationFrequencyPathway and consequences of alterationClinical relevanceReference
PAX5 Focal deletions, translocations, and sequence mutations 30% of B-ALL Transcription factor required for B-lymphoid development; mutations impair DNA binding and transcriptional activation Important in leukemogenesis, but not associated with adverse outcome 3-5 
IKZF1 Focal deletions or sequence mutations 15% of all pediatric B-ALL cases, including 70%-80% of BCR-ABL1-positive ALL and one-third of high-risk BCR-ABL1-negative B-ALL Transcription factor required for development of HSC to lymphoid precursor; deletions and mutations result in loss of function or dominant-negative isoforms Associated with poor outcome 4, 5, 7, 51, 102 
JAK1/2 Pseudokinase and kinase domain mutations 18%-35% of DS ALL and 10.7% high-risk BCR-ABL1-negative ALL Constitutive JAK-STAT activation Potential for targeting with TKIs that inhibit JAK1/2 8, 39, 43 
CRLF2 Rearrangement as IGH-CRLF2 or P2RY8-CRLF2 resulting in overexpression 5%-16% of pediatric and adult B-ALL and >50% DS ALL; 50% of Ph-like ALL Associated with mutant JAK in up to 50% of cases; CRLF2 mutations and JAK mutations are cotransforming in cell lines/F3 cells and result in constitutive STAT activation; in high-risk B-ALL, associated with IKZF1 alterations, JAK mutations, and poor outcome Detected by flow cytometry or molecular assays; potential for targeting with JAK inhibitors 6, 29, 41, 42, 44 
Kinase-activating alterations in Ph-like ALL Rearrangements of 13 cytokine receptors and tyrosine kinases; sequence mutations of IL7R and FLT; deletions of SH2B3 10% childhood B-ALL, up to 30% ALL in adult ALL; associated with Ph-like gene expression profile Activation of kinase signaling pathways and amenable to TKI therapy Associated with high-risk features and increased risk of relapse; anecdotal reports of response to TKI therapy 14, 22, 30, 54 
NOTCH1 Mutations, rarely deletions >60% T-ALL Activation of NOTCH1 signaling; mutations in FBXW7 and PTEN also influence NOTCH1 signaling and prognosis Key pathogenic lesion in T-ALL; direct targeting limited by toxicity; variable associations with outcome 62  
CREBBP Focal deletion and sequence mutations 19% of relapsed ALL; also mutated in non-Hodgkin lymphoma Mutations result in impaired histone acetylation and transcriptional regulation Mutations selected for at relapse and associated with glucocorticoid resistance 11, 35 
NT5C2 Focal mutations Up to 20% relapsed mutation Mutations in gain of function Mutations selected at relapse and associated with resistance to thiopurines 17, 84 
TP53 Deletions and focal mutations ∼90% of LH ALL, otherwise uncommon in predominant clone at diagnosis Frequently germline in LH ALL; confer resistance to therapy Hallmark of LH ALL at diagnosis; associated with disease relapse 15, 83 
GeneAlterationFrequencyPathway and consequences of alterationClinical relevanceReference
PAX5 Focal deletions, translocations, and sequence mutations 30% of B-ALL Transcription factor required for B-lymphoid development; mutations impair DNA binding and transcriptional activation Important in leukemogenesis, but not associated with adverse outcome 3-5 
IKZF1 Focal deletions or sequence mutations 15% of all pediatric B-ALL cases, including 70%-80% of BCR-ABL1-positive ALL and one-third of high-risk BCR-ABL1-negative B-ALL Transcription factor required for development of HSC to lymphoid precursor; deletions and mutations result in loss of function or dominant-negative isoforms Associated with poor outcome 4, 5, 7, 51, 102 
JAK1/2 Pseudokinase and kinase domain mutations 18%-35% of DS ALL and 10.7% high-risk BCR-ABL1-negative ALL Constitutive JAK-STAT activation Potential for targeting with TKIs that inhibit JAK1/2 8, 39, 43 
CRLF2 Rearrangement as IGH-CRLF2 or P2RY8-CRLF2 resulting in overexpression 5%-16% of pediatric and adult B-ALL and >50% DS ALL; 50% of Ph-like ALL Associated with mutant JAK in up to 50% of cases; CRLF2 mutations and JAK mutations are cotransforming in cell lines/F3 cells and result in constitutive STAT activation; in high-risk B-ALL, associated with IKZF1 alterations, JAK mutations, and poor outcome Detected by flow cytometry or molecular assays; potential for targeting with JAK inhibitors 6, 29, 41, 42, 44 
Kinase-activating alterations in Ph-like ALL Rearrangements of 13 cytokine receptors and tyrosine kinases; sequence mutations of IL7R and FLT; deletions of SH2B3 10% childhood B-ALL, up to 30% ALL in adult ALL; associated with Ph-like gene expression profile Activation of kinase signaling pathways and amenable to TKI therapy Associated with high-risk features and increased risk of relapse; anecdotal reports of response to TKI therapy 14, 22, 30, 54 
NOTCH1 Mutations, rarely deletions >60% T-ALL Activation of NOTCH1 signaling; mutations in FBXW7 and PTEN also influence NOTCH1 signaling and prognosis Key pathogenic lesion in T-ALL; direct targeting limited by toxicity; variable associations with outcome 62  
CREBBP Focal deletion and sequence mutations 19% of relapsed ALL; also mutated in non-Hodgkin lymphoma Mutations result in impaired histone acetylation and transcriptional regulation Mutations selected for at relapse and associated with glucocorticoid resistance 11, 35 
NT5C2 Focal mutations Up to 20% relapsed mutation Mutations in gain of function Mutations selected at relapse and associated with resistance to thiopurines 17, 84 
TP53 Deletions and focal mutations ∼90% of LH ALL, otherwise uncommon in predominant clone at diagnosis Frequently germline in LH ALL; confer resistance to therapy Hallmark of LH ALL at diagnosis; associated with disease relapse 15, 83 

DS, Down syndrome; HSC, hematopoietic stem cell; NR, none reported.

Figure 2

Schema for the genetic pathogenesis of B-ALL. Key inherited and somatic genomic variants and their relationship to the development of ALL and treatment failure are shown. Representative alterations are shown.

Figure 2

Schema for the genetic pathogenesis of B-ALL. Key inherited and somatic genomic variants and their relationship to the development of ALL and treatment failure are shown. Representative alterations are shown.

Close modal

The frequency of somatic mutations in ALL is low (<20 nonsilent mutations per case),13,15,18,22  with exceptions being occasional relapse cases with hypermutator phenotypes.35  Indeed, MLL-rearranged infant ALL has one of the lowest mutational frequencies in human cancer.36  The most common type of structural genetic alterations in ALL are focal deletions arising from aberrant activity of the recombinase activating genes.5,20 

Genes encoding transcriptional regulators of lymphoid development are among the most frequently mutated genes, particularly in B-ALL. These include PAX5, IKZF1, and EBF1 that encode DNA-binding transcription factors required for lymphoid development. Most common are somatic deletions or sequence mutations of PAX5 and IKZF1, and less common are translocations of PAX5 and deletions of EBF1.4  Each results in loss of function or expression of dominant-negative alleles and impaired lymphoid maturation that contributes to leukemogenesis.37,38 

Additional commonly altered pathways in ALL include tumor suppression and cell-cycle regulation (TP53, RB1, and CDKN2A/CDKN2A); cytokine receptor, tyrosine kinase, and Ras signaling (ABL1, ABL2, CRLF2, CSF1R, EPOR, FLT3, IL2RB, IL7R, JAK1/2/3, NTRK3, and PDGFRB), Ras signaling (NF1, KRAS, NRAS, and PTPN11), and epigenetic modification (EZH2, CREBBP, SETD2, MLL2 [KMT2D], and NSD2 [WHSC1]).4,7,39  The type of alteration (chromosomal rearrangement, deletion/amplification, or sequence mutation) and gene involved varies between subtypes.39  For example, IKZF1 alterations are a hallmark of BCR-ABL1–positive and Ph-like ALL5 ; in contrast, other members of the IKAROS transcription factor family, IKZF2 and IKZF3, are selectively mutated in hypodiploid ALL.15  Several key genetic alterations are predictive of outcome, including the association of IKZF1 alterations with treatment failure in both BCR-ABL1–positive and Ph-like ALL.7,40 

Ph-like ALL cases lack BCR-ABL1, exhibit a gene expression profile similar to BCR-ABL1–positive ALL, harbor alterations of B lymphoid transcription factor genes, and have poor outcome.7,30  The prevalence of Ph-like ALL increases with age and varies according to ethnicity, in part because CRLF2 alterations are associated with Hispanic ethnicity and native American genetic ancestry.41 

Ph-like ALL is characterized by a diverse range of genetic alterations that dysregulate cytokine receptor and tyrosine kinase signaling (Table 3 and Figure 3).14,22  Analysis of over 1700 cases of B-ALL identified several types of kinase alteration in Ph-like ALL: rearrangements of CRLF2 (47% of cases), rearrangements of ABL-class tyrosine kinase genes (12%), rearrangements of JAK2 (7%) and EPOR (10%), mutations activating Janus kinase and signal transducer and activator of transcription (JAK-STAT) signaling (11%) and Ras (6%), and less common kinase alterations (NTRK3 and PTK2B).

Table 3

Kinase rearrangements and therapeutic targets in Ph-like ALL

KinasePotential TKINumber of gene partnersNumber of cases5′ genes
ABL1 Dasatinib 14 ETV6, NUP214, RCSD1, RANBP2, SNX2, and ZMIZ1 
ABL2 Dasatinib PAG1, RCSD1, and ZC3HAV1 
CSF1R Dasatinib SSBP2 
PDGFRB Dasatinib 11 EBF1, SSBP2, TNIP1, and ZEB2 
CRLF2 JAK2 inhibitor 30 IGH and P2RY8 
JAK2 JAK2 inhibitor 10 19 ATF7IP, BCR, EBF1, ETV6, PAX5, PPFIBP1, SSBP2, STRN3, TERF2, and TPR 
EPOR JAK2 inhibitor IGH and IGK 
DGKH Unknown ZFAND3 
IL2RB JAK1/JAK3 inhibitor MYH9 
NTRK3 Crizotinib ETV6 
PTK2B FAK inhibitor KDM6A and STAG2 
TSLP JAK2 inhibitor IQGAP2 
TYK2 TYK2 inhibitor MYB 
KinasePotential TKINumber of gene partnersNumber of cases5′ genes
ABL1 Dasatinib 14 ETV6, NUP214, RCSD1, RANBP2, SNX2, and ZMIZ1 
ABL2 Dasatinib PAG1, RCSD1, and ZC3HAV1 
CSF1R Dasatinib SSBP2 
PDGFRB Dasatinib 11 EBF1, SSBP2, TNIP1, and ZEB2 
CRLF2 JAK2 inhibitor 30 IGH and P2RY8 
JAK2 JAK2 inhibitor 10 19 ATF7IP, BCR, EBF1, ETV6, PAX5, PPFIBP1, SSBP2, STRN3, TERF2, and TPR 
EPOR JAK2 inhibitor IGH and IGK 
DGKH Unknown ZFAND3 
IL2RB JAK1/JAK3 inhibitor MYH9 
NTRK3 Crizotinib ETV6 
PTK2B FAK inhibitor KDM6A and STAG2 
TSLP JAK2 inhibitor IQGAP2 
TYK2 TYK2 inhibitor MYB 

Data are from Roberts et al.22 

Figure 3

Frequency of subtypes of Ph-like ALL. Combined prevalence of Ph-like ALL subtypes in children, adolescents, and young adults including CRFL2-rearranged JAK2 mutant (CRLF2r_JAK2 mut) and CRFL2-rearranged JAK2 wild-type (CRFL2r_JAK2 WT), ABL1-class rearrangements (ABL1, ABL2, CSF1R, and PDGFRB), JAK2 and EPOR rearrangements and other mutations in JAK-STAT signaling (FLT3, IL7R, SH2B3, JAK1/3, TYK2, IL2RB, and TSLP), Ras mutations (KRAS, NRAS, NF1, PTPN11, and BRAF), and unknown alterations. Data from Roberts et al.22  HR, high-risk.

Figure 3

Frequency of subtypes of Ph-like ALL. Combined prevalence of Ph-like ALL subtypes in children, adolescents, and young adults including CRFL2-rearranged JAK2 mutant (CRLF2r_JAK2 mut) and CRFL2-rearranged JAK2 wild-type (CRFL2r_JAK2 WT), ABL1-class rearrangements (ABL1, ABL2, CSF1R, and PDGFRB), JAK2 and EPOR rearrangements and other mutations in JAK-STAT signaling (FLT3, IL7R, SH2B3, JAK1/3, TYK2, IL2RB, and TSLP), Ras mutations (KRAS, NRAS, NF1, PTPN11, and BRAF), and unknown alterations. Data from Roberts et al.22  HR, high-risk.

Close modal

ABL-class rearrangements encode fusion genes involving ABL1, ABL2 (ARG), CSF1R (encoding the macrophage colony stimulating factor receptor), and PDGFRB.14,22  Multiple fusion partners have been identified, each involving the kinase as the downstream partner and preserving an intact kinase domain (Figure 4). JAK2 is rearranged to at least 14 different partner genes in Ph-like ALL. EPOR rearrangements include reciprocal or cryptic translocations with immunoglobulin and other loci (eg, IGH and IGK) that deregulate receptor expression and also truncate EPOR, causing increased JAK-STAT signaling.14,22 

Figure 4

ABL1-class rearrangements in Ph-like ALL. The figure shows each ALL sample as a column, each kinase rearrangement as a green box, and the diverse range of fusion partners in blue. On the right, representative schema of fusion proteins are shown, showing preservation of the kinase domain in the C terminus of the protein and fusion partners uniformly in the 5′ region of the protein, with domains that mediate overexpression of the kinase, cellular mislocalization, and dimerization of the fusion protein. TKD, tyrosine kinase domain.

Figure 4

ABL1-class rearrangements in Ph-like ALL. The figure shows each ALL sample as a column, each kinase rearrangement as a green box, and the diverse range of fusion partners in blue. On the right, representative schema of fusion proteins are shown, showing preservation of the kinase domain in the C terminus of the protein and fusion partners uniformly in the 5′ region of the protein, with domains that mediate overexpression of the kinase, cellular mislocalization, and dimerization of the fusion protein. TKD, tyrosine kinase domain.

Close modal

CRLF2 encodes cytokine receptor like factor 2, also known as the thymic stromal-derived lymphopoietin receptor (TSLPR) that forms a heterodimeric receptor with the interleukin-7 receptor α chain (IL7Rα) for thymic stromal lymphopoietin (TSLP). CRLF2 is rearranged to the immunoglobulin heavy chain locus (IGH-CRLF2) or by a deletion upstream of CRLF2 that results in expression of P2RY8-CRLF2.6,29,41 CRLF2 rearrangements are most common in Ph-like and Down syndrome–associated ALL and are age dependent, with P2RY8-CRLF2 associated with young age and IGH-CRLF2 with older age and Hispanic ancestry.6,29  Less common are activating CRLF2 point mutations (eg, p.Phe232Cys).42  The majority of CRLF2-rearranged cases have additional alterations driving JAK-STAT or Ras signaling, particularly activating JAK1 or JAK2 mutations.6,29,43  The most frequent site of mutation is p.Arg683 in the JAK2 pseudokinase domain, but mutations also occur in the pseudokinase domain of JAK1 and the kinase domains of JAK1 and JAK2.8  Other mutations observed in CRLF2-rearranged cases include IL7R sequence mutations, SH2B3 deletions, TSLP rearrangements, and Ras mutations.8,22 

In most studies, CRLF2 rearrangements are associated with poor prognosis, particularly in cases with concomitant IKZF1 alteration.41,44 CRLF2-rearranged cells exhibit activated JAK-STAT, phosphatidylinositol 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR), and BCL-2 signaling, and therapies targeting these pathways alone or in combination have shown efficacy in preclinical models.45,46 

Other alterations that activate kinase signaling in Ph-like ALL include those activating IL7R, FLT3, IL2RB (interleukin 2 receptor subunit β), JAK1 or JAK3, or loss-of-function deletions/mutations of SH2B3 (LNK), a negative regulator of JAK-STAT signaling.47  IL7R mutations are also observed in T-cell precursor ALL (T-ALL) and B-ALL.13,48,49  These mutations are often in the transmembrane domain and cause constitutive JAK-STAT signaling that may be abrogated with JAK inhibitors.13,50 

A minority of Ph-like cases have mutations activating Ras signaling (NRAS, KRAS, PTPN11, and NF1),22  although these are not exclusively observed in Ph-like ALL. Several kinases are infrequently rearranged in Ph-like ALL, including NTRK3 and TYK2.22 

Ph-like ALL is associated with high-risk clinical features, a poor response to induction chemotherapy, elevated minimal residual disease (MRD) levels, and/or poor survival.7,14,22,30,51,52  Several observations indicate that tyrosine kinase inhibitors (TKIs) may be effective in Ph-like ALL. Kinase fusions and sequence mutations confer cytokine-independent proliferation in mouse pre–B-cell lines that is abrogated by tyrosine kinase inhibitors (TKIs), ABL1 inhibitors such as imatinib and dasatinib for ABL-class fusions, and JAK2 inhibitors for JAK-STAT–activating alterations.14,22,53  Human Ph-like leukemic cells show similar pathway activation and sensitivity to TKI in vitro and in xenograft models. There are several reports of Ph-like ALL with ABL-class rearrangements poorly responsive to chemotherapy with profound TKI responses,22,54  which have led to prospective precision medicine trials of TKI therapy in Ph-like ALL.

Hypodiploid B-ALL (<44 chromosomes) is associated with poor outcome.27,28  Several subgroups of hypodiploid ALL are recognized. The most common are near-haploid (NH, 24-31 chromosomes) and low-hypodiploid (LH, 32-39 chromosomes) ALL, which have distinct transcriptional profiles and submicroscopic genetic alterations.15  High-hypodiploid (40-43 chromosomes) ALL is rare, and near-diploid ALL (44 or 45 chromosomes) is a distinct entity frequently characterized by ETV6-RUNX1 fusion or rearrangements forming dicentric chromosomes.

NH ALL is characterized by Ras-activating mutations, most commonly focal deletions of NF1, but also NRAS, KRAS, and PTPN11 mutations, and inactivation of IKZF3.15  LH ALL is characterized by biallelic alteration of TP53, deletions of CDKN2A/B and RB1, and inactivation of IKZF2.15 TP53 mutations are germline in half of childhood LH ALL, making this a manifestation of Li-Fraumeni syndrome requiring clinical TP53 mutation testing. Germline mutations in other oncogenes are also observed in hypodiploid ALL, including NRAS and PTPN11.15  Hypodiploid ALL leukemic cells exhibit activation of PI3K/mTOR and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) signaling that is sensitive to monotherapy with PI3K inhibitors, but not mitogen-activated protein kinase kinase inhibitors, as well as BCL2 inhibitors, and the potential for these agents in this high-risk ALL subset is currently being tested in preclinical studies.

Approximately 7% of childhood and adult B-ALL cases have a distinct gene expression profile but lack a unifying chromosomal rearrangement.55  Most have a focal deletion of ERG,56,57  which encodes an ETS family transcription factor also rearranged in prostate cancer.58  These cases often express an aberrant ERG protein. IKZF1 alterations are relatively common in ERG-altered ALL but, in contrast to BCR-ABL1–positive and Ph-like ALL, are not associated with inferior outcome.57,59 

Intrachromosomal amplification of chromosome 21 (iAMP21), defined as gain of at least 3 copies of part of chromosome 21 incorporating RUNX1, occurs in ∼2% of B-ALL and is associated with older age at diagnosis and poor outcome.60  The structural alterations identified in iAMP21 are usually complex with large regions of amplification and commonly flanking deletions.21  iAMP21 is usually observed in cases lacking a recurring chromosomal translocation, but its risk is increased several-thousand-fold in persons with a constitutional Robertsonian t(15;21).21 

T-ALL is also characterized by translocations that deregulate transcription factors, commonly by rearrangement to T-cell antigen receptor loci, and recurring sequence mutations and DNA copy-number alterations that disrupt developmental, signaling, and tumor suppressor pathways, including BCL11B,61 NOTCH1,62 FBXW7,63 MYB,64 PTEN,65 RB1, and additional genes whose role in the pathogenesis of T-ALL remains to be elucidated, including PHF610  and WT1.9,66 

Early T-cell precursor (ETP) ALL is a recently described subtype of high-risk ALL defined by reduced expression of T-cell markers (CD1a, CD8, and CD5) and aberrant expression of myeloid or stem cell markers.67  Many studies reported poor outcome of ETP ALL,67,68  but this is mitigated by contemporary risk-adapted therapy.69,70 

ETP ALL is genetically heterogeneous, with mutation of multiple cellular pathways including (1) hematopoietic and lymphoid development (RUNX1, IKZF1, ETV6, GATA3, and EP300); (2) Ras, cytokine receptor, and kinase signaling (NRAS, IL7R, KRAS, JAK1, JAK3, NF1, PTPN11, and SH2B3); and (3) loss-of-function mutations targeting epigenetic regulators.12,13,71,72  These commonly involve the polycomb repressor complex 2 (PRC2; EZH2, SUZ12, and EED), which mediates histone 3 lysine 27 (H3K27) trimethylation and repression of gene transcription, and SETD2, which encodes a H3K36 trimethylase that marks actively transcribed genes.

The gene expression profile of ETP ALL is similar to that of hematopoietic stem cells, suggesting that ETP ALL may be one of a spectrum of neoplasms of hematopoietic stem cells and progenitors that retain multilineage potential, including “near” ETP ALL (with normal CD5 expression) and mixed-phenotype acute leukemia. Existing data indicate that these forms of leukemia harbor mutations targeting similar genes and pathways.73  The involvement of JAK-STAT and PRC2 pathways in ETP ALL suggests that JAK inhibition and/or chromatin-modifying agents may be therapeutically useful.49,50,74 

Recent studies have provided additional insights into the biology of T-ALL. Exome sequencing identified recurrent mutations in ribosomal proteins and CNOT3, which encodes part of a transcriptional regulatory complex.18  Mutations and chimeric fusions involving kinases observed in B-ALL have also been identified in T-ALL including ABL1,75 PTK2B (FAK), and JAK2,19  suggesting a subset of T-ALL may also be amenable to targeted therapy with TKIs.

Noncoding genomic alterations are also important in T-ALL.23,24  A recent study identified novel long noncoding RNAs in T-ALL, including several regulated by NOTCH1.23  One long noncoding RNA was examined in detail and found to regulate oncogenic signaling through the insulin-like growth factor-1 receptor.23 

Intriguingly, a noncoding region 1.5 Mb distal to MYC is commonly duplicated in T-ALL, is controlled by NOTCH1, and regulates expression of MYC.24  Targeted disruption of this region in a mouse model demonstrated that this locus was important for leukemogenesis and provides an explanation for the previously observed regulation of MYC expression by NOTCH1 in T-ALL.76 

Another mechanism of leukemogenesis in T-ALL is mutations upstream of the T-ALL oncogene TAL1, which generate a binding site for the MYB transcription factor, thereby recruiting a protein complex including TAL1 and the H3K27 acetylator CREBBP, resulting in formation of an oncogenic “superenhancer” region characterized by high levels of H3K27 acetylation.25  These examples underscore the importance of careful integrated analysis of coding and noncoding genomic, transcriptomic, and epigenomic features in ALL.

Multiple studies have identified mutations in genes encoding epigenetic regulators and mutations in noncoding regions of the genome that are modified by such regulators. Furthermore, mutations in epigenetic modifiers such as CREBBP and SETD2 are enriched at relapse.11,35,77 

Alterations in cytosine methylation are also important in leukemogenesis. Leukemia cells typically exhibit global hypomethylation, with selective hypermethylation of CpG-rich regions in gene promoters. Promoter hypermethylation is associated with gene silencing and hypomethylation with transcriptional activation. Genome-wide profiling of cytosine methylation, gene expression, and DNA copy-number alterations has shown recently that ALL subtypes have distinct methylation and gene expression signatures and that methylation is an important determinant of ALL gene expression. Methylation perturbations may be a consequence of the founding genetic alterations and/or cooperate with structural genetic changes to promote leukemogenesis.78,79 

Mutations in genes encoding epigenetic regulators and chromatin-modifying proteins have been identified in most subtypes of ALL. In addition to PRC2 mutations in ETP ALL,13,71  notable examples are mutations of WHSC1 (NSD2) in ETV6-RUNX1 ALL,80  and mutation of CREBBP (a H3K18, H3K27, and nonhistone acetyl transferase), SETD2 (a H3K36 trimethylase), KDM6A, and MLL2 in relapsed and hypodiploid ALL.11,15,35,77  Consequently, there is interest in testing the efficacy of drugs that modulate histone modifications in ALL, including inhibitors of bromodomain readers,81  histone demethylases,82  and histone deacetylases.

Most diagnostic ALL samples exhibit clonal diversity, and this diversity evolves over time. Analysis of paired diagnosis/relapse specimens has shown that most cases exhibit substantial genomic changes during disease progression, with acquisition of new deletions and mutations, and loss of diagnosis-specific lesions.34  Founding chromosomal translocations are almost usually conserved from diagnosis to relapse, along with a proportion of DNA copy-number alterations and point mutations in most cases. Many deletions or mutations that emerge in the predominant relapse clone may be detected at low levels at diagnosis using sensitive technology.35  Together, these findings indicate that the predominant clones observed at diagnosis and relapse clones arise from a common “ancestral” or “preleukemic” clone that harbors some of the genetic alterations required for leukemogenesis but then evolves down multiple paths. Treatment dramatically influences this evolution and clonal composition by suppressing or eradicating one or more of the predominant clones at diagnosis and facilitating the emergence of subclones that harbor and/or acquire mutations that confer resistance to therapy.

Genome sequencing, coupled with deep coverage of mutated sites, has enabled this clonal structure and temporal progression to be dissected with precision.35  First, many relapse-acquired lesions involve genes regulating B-cell development (IKZF1), tumor suppression (TP53),83  Ras signaling, chromatin modification (CREBBP and SETD2),77  and drug metabolism (NT5C2).17,35,84  Second, relapse-acquired alterations may induce a more stem cell–like state (eg, IKZF1) or directly confer resistance to individual chemotherapeutic agents (eg, CREBBP and NT5C2). CREBBP mutations result in resistance to glucocorticoids,11  and mutations in the 5′-nucleotidase gene NT5C2 result in resistance to nucleoside analogs.84  Third, many cases have multiple subclonal mutations involving the same pathway or gene at diagnosis. Initial chemotherapy results in suppression or elimination of all but one usually minor clone that survives to acquire additional mutations that confer resistance to therapy and propagate relapse.35  Finally, many mutations present in the predominant clone at relapse may be detected at early time points in therapy. This is important given the increasing application of next-generation sequencing approaches to MRD detection.85 

In the last few years, there have been growing data supporting an important role of common inherited variants and rare deleterious mutations in risk of developing ALL.

Genome-wide association studies using microarrays to genotype millions of single-nucleotide polymorphisms in cases and ethnically matched controls have identified associations between polymorphisms in genes including IKZF1, ARID5B, CEBPE, CDKN2A, and GATA3 and the risk of developing ALL.86-90  Associations with specific ALL subtypes and relapse have also been identified.91-95  Several genes such as IKZF1, CEBPE, and GATA3 encode transcription factors that are also targets of somatic genetic alteration in ALL.96 CDKN2A/B encode the INK4/ARF family of tumor suppressors and cell-cycle regulators; this locus is commonly deleted in B- and T-ALL. In addition, ARID5B polymorphisms are associated with ALL risk and outcome in specific ethnic groups,92  and GATA3 variants are associated with Ph-like ALL.94 

Deleterious germline mutations have been identified in familial and sporadic ALL. In addition to the germline TP53 and Ras mutations observed in LH ALL,15  additional hypodiploid cases harbor germline mutations involving genes mediating DNA repair that are likely to be pathogenic.15  Down syndrome is associated with an increased risk of AML and ALL, and the rare constitutional Robertsonian translocation rob(15;21)(q10;q10)c is associated with a markedly increased risk of ALL with iAMP21.21  Familial ALL is uncommon, but such kindreds are highly informative. Two studies have reported kindreds with autosomal-dominant ALL, in which affected individuals harbored a novel germline PAX5 mutation, p.Gly183Ser, that attenuated the transcriptional activity of PAX5.97  Leukemic cells exhibited loss of the nonmutated PAX5 allele by deletion of chromosome 9p, suggesting that germline heterozygosity of this variant is tolerated but that severe attenuation of PAX5 activity is required for leukemogenesis.97  Recent reports have described several kindreds with deleterious inherited mutations in the ETS domain of ETV6,98,99  a common target of mutation and rearrangement in leukemia.

One can envisage several opportunities for incorporating genomic discoveries into ALL management, from initial diagnosis and risk stratification to the delivery of targeted therapy. Sequencing will be increasingly used for molecular diagnosis and will likely supplant current approaches that require multiple complex cytogenetic and molecular tests that are unable to identify all clinically relevant genomic alterations. Notable examples include ERG-deregulated and Ph-like ALL, which are either not evident on conventional cytogenetic analysis or are highly genetically heterogeneous. Diagnostic sequencing approaches must be capable of identifying sequence alterations, DNA copy-number alterations, and structural rearrangements in ALL. Thus, it is likely that genome-wide sequencing approaches, with their attendant challenges in turnaround time and interpretation, will be increasingly adopted as a diagnostic approach.

Second, sequencing will identify subtypes and specific genetic alterations with prognostic importance, and the potential role of these in risk stratification must be clarified. Current risk-stratification algorithms consider a limited range of genetic information (eg, aneuploidy and selected rearrangements) with age, initial white blood cell count, central nervous system involvement, and MRD response.100  Such algorithms have improved survival by optimizing use of intensive chemotherapy regimens and by limiting the use of prophylactic cranial irradiation.101  Genomic features such as IKZF1 alterations, CRLF2 rearrangement, iAMP21, and Ph-like ALL are associated with poor outcome in many studies,14,22  but their ability to refine prognosis in studies incorporating intensive therapy and MRD measurement has varied or has been difficult to measure due to complexity of testing or small sample sizes.52,102  Also, the prognostic importance of specific alterations is subtype dependent, with interplay between molecular lesions. For example, IKZF1 alterations are associated with poor outcome in B-ALL, with the exception of ERG-altered ALL. Thus, comprehensive genomic studies in large cohorts treated with current therapies, including treatment modifications based upon MRD response, are required.

Third, sequencing will identify targets or pathways to guide implementation of novel therapies, either in frontline studies or following relapse, particularly for high-risk ALL subtypes with poor outcomes amenable to treatment with currently approved agents.103  The paradigm for precision medicine in leukemia is the use of ABL-class TKIs in chronic myeloid leukemia and combination therapy with TKIs and chemotherapy in Ph+ ALL.104,105  Although important questions remain in Ph+ ALL (including the optimal TKI, the optimal chemotherapy backbone, the length of TKI therapy, the role of allogeneic hematopoietic stem cell transplantation in first remission, and the role of TKIs after hematopoietic stem cell transplantation), any patient diagnosed with Ph+ ALL in the United States or western Europe will receive a TKI as part of therapy. There is consequently enthusiasm to extend TKI therapy to Ph-like ALL, but it is critical to determine whether kinase-activating alterations are similar drivers to BCR-ABL1; that is, to show that they arise early in disease development, that they are present in all subclones at all stages of disease, and that the leukemia is dependent upon continued activity of the mutant kinase.

Subsets of Ph-like ALL, including those with ABL-class, JAK2, and EPOR rearrangements, appear to fulfill the above requirements. ABL-class fusions phenocopy BCR-ABL1 in both transforming function and TKI sensitivity in experimental models, and there are anecdotal reports of remarkable short-term responses to ABL-class TKIs in refractory Ph-like ALL. Thus, clinical trials using these agents are being developed by multiple groups including the Children’s Oncology Group (COG) and St. Jude Children’s Research Hospital. Given this, it is essential to consider how Ph-like ALL is identified and the complex underlying genomic landscape dissected. One may focus on selective testing for subsets of alterations, screening for the Ph-like gene expression profile, and/or genome sequencing approaches. We emphasize that the most important goal is to identify underlying kinase-activating lesions (eg, ABL-class fusions) rather than the gene expression profile that defines Ph-like ALL. This may be accomplished by focused molecular/fluorescence in situ hybridization assays for known fusions and rearrangements, coupled with selective genome sequencing for enigmatic cases (the approach adopted for the large cohorts studied by the COG), or sequencing of all patients at the time of diagnosis. To establish TKI efficacy, the ideal approach would be to conduct a randomized trial of chemotherapy with or without TKIs. This is likely not feasible, and establishing benefit will rely more upon trials that use historical control comparisons, as the COG did with imatinib in Ph+ ALL.104 

It will be even more challenging to extend precision medicine approaches to other genetically defined subsets of ALL, as few recapitulate the key features of BCR-ABL1 ALL. A number of pathways are recurrently mutated in B- and T-ALL, including NOTCH1 in T-ALL, epigenetic modifiers in both B- and T-ALL, transcription factors involved in B-cell differentiation, the Ras pathway, and others. Moreover, it is likely that combinatorial therapy with drugs targeting multiple “nodes” in perturbed signaling pathways will be effective.46  Although there are promising new drugs and preliminary preclinical data in support of these approaches, data justifying use in front-line ALL therapy are lacking. It will be critical to conduct clinical trials that are designed to clearly establish whether or not new therapies improve outcome.

Finally, sequencing is likely to have an important role in monitoring response to therapy, by deeply sequencing antigen receptor loci85  or other targets of genetic alteration, particularly those known to facilitate resistance to therapy (for example, IKZF1, CREBBP, and NT5C2).106  Sequencing of antigen receptor loci has shown promise as an alternative to flow cytometric or polymerase chain reaction–based assays. An important challenge for future studies is deploying technology to sensitively detect mutations and structural changes and to determine how such information may be used to change therapy when a mutation that confers resistance to a specific agent emerges.

The ALL genome remains a work in progress. The number of comprehensively sequenced ALL genomes is small, particularly in older individuals. In existing data sets, the number of frequently mutated genes is typically low, with a “long tail” of infrequently mutated genes. Thus, we need to sequence many more cases broadly to systematically and comprehensively identify all relevant coding and noncoding alterations. This will be important to more completely understand the key pathways driving leukemia development and to inform the interpretation of clinical sequencing efforts. We will likely also see much greater use of single-cell sequencing technologies to profile structural alterations, transcriptional profiles, and epigenomic marks. This will be especially useful to gain a fuller understanding of the role of clonal composition and dynamics in ALL. An important challenge is experimental validation of the functional effects of the identified mutations. There have been few faithful models of ALL, in part due to the poor understanding of the polygenic basis of this disease. We are now at a new dawn where we have the genomic information to build the right models of leukemia and to use these to test new therapies to improve patient outcome.

The authors thank their colleagues at St. Jude Children’s Research Hospital, the Children’s Oncology Group, and the National Cancer Institute Therapeutically Applicable Research to Generate Effective Treatments (TARGET) consortium (https://ocg.cancer.gov/programs/target). Several of the studies described were supported by the American Lebanese Syrian Associated Charities of St. Jude Children’s Research Hospital, the National Cancer Institute of the US National Institutes of Health, Alex’s Lemonade Stand Foundation, the American Association for Cancer Research, the American Society of Hematology, the Henry Schueler 41&9 Foundation, the Leukemia and Lymphoma Society. The National Health and Medical Research Council (Australia), the Pew Charitable Trusts, Stand Up To Cancer, and the St. Baldrick’s Foundation. The authors apologize to authors of the many excellent manuscripts that could not be cited due to space considerations.

Contribution: S.P.H. and C.G.M. reviewed the literature and wrote the manuscript.

Conflict-of-interest disclosure: S.P.H. and C.G.M. are inventors on patent 8 568 964 “Identification of novel subgroups of high-risk pediatric precursor-B cell acute lymphoblastic leukemia, outcome correlations and diagnostic and therapeutic methods related to same.”

Correspondence: Stephen P. Hunger, Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Colket Translational Research Building, Room 3060, 3501 Civic Center Blvd, Philadelphia, PA 19104; e-mail: hungers@email.chop.edu; and Charles G. Mullighan, St. Jude Children’s Research Hospital, 262 Danny Thomas Pl, Mail Stop 342, Memphis, TN 38105, e-mail: charles.mullighan@stjude.org.

1
Inaba
 
H
Greaves
 
M
Mullighan
 
CG
Acute lymphoblastic leukaemia.
Lancet
2013
, vol. 
381
 
9881
(pg. 
1943
-
1955
)
2
Nguyen
 
K
Devidas
 
M
Cheng
 
SC
et al. 
Children’s Oncology Group
Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group study.
Leukemia
2008
, vol. 
22
 
12
(pg. 
2142
-
2150
)
3
Kuiper
 
RP
Schoenmakers
 
EF
van Reijmersdal
 
SV
et al. 
High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression.
Leukemia
2007
, vol. 
21
 
6
(pg. 
1258
-
1266
)
4
Mullighan
 
CG
Goorha
 
S
Radtke
 
I
et al. 
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.
Nature
2007
, vol. 
446
 
7137
(pg. 
758
-
764
)
5
Mullighan
 
CG
Miller
 
CB
Radtke
 
I
et al. 
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.
Nature
2008
, vol. 
453
 
7191
(pg. 
110
-
114
)
6
Mullighan
 
CG
Collins-Underwood
 
JR
Phillips
 
LA
et al. 
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.
Nat Genet
2009
, vol. 
41
 
11
(pg. 
1243
-
1246
)
7
Mullighan
 
CG
Su
 
X
Zhang
 
J
et al. 
Children’s Oncology Group
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
N Engl J Med
2009
, vol. 
360
 
5
(pg. 
470
-
480
)
8
Mullighan
 
CG
Zhang
 
J
Harvey
 
RC
et al. 
JAK mutations in high-risk childhood acute lymphoblastic leukemia.
Proc Natl Acad Sci USA
2009
, vol. 
106
 
23
(pg. 
9414
-
9418
)
9
Tosello
 
V
Mansour
 
MR
Barnes
 
K
et al. 
WT1 mutations in T-ALL.
Blood
2009
, vol. 
114
 
5
(pg. 
1038
-
1045
)
10
Van Vlierberghe
 
P
Palomero
 
T
Khiabanian
 
H
et al. 
PHF6 mutations in T-cell acute lymphoblastic leukemia.
Nat Genet
2010
, vol. 
42
 
4
(pg. 
338
-
342
)
11
Mullighan
 
CG
Zhang
 
J
Kasper
 
LH
et al. 
CREBBP mutations in relapsed acute lymphoblastic leukaemia.
Nature
2011
, vol. 
471
 
7337
(pg. 
235
-
239
)
12
Van Vlierberghe
 
P
Ambesi-Impiombato
 
A
Perez-Garcia
 
A
et al. 
ETV6 mutations in early immature human T cell leukemias.
J Exp Med
2011
, vol. 
208
 
13
(pg. 
2571
-
2579
)
13
Zhang
 
J
Ding
 
L
Holmfeldt
 
L
et al. 
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
Nature
2012
, vol. 
481
 
7380
(pg. 
157
-
163
)
14
Roberts
 
KG
Morin
 
RD
Zhang
 
J
et al. 
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.
Cancer Cell
2012
, vol. 
22
 
2
(pg. 
153
-
166
)
15
Holmfeldt
 
L
Wei
 
L
Diaz-Flores
 
E
et al. 
The genomic landscape of hypodiploid acute lymphoblastic leukemia.
Nat Genet
2013
, vol. 
45
 
3
(pg. 
242
-
252
)
16
Perez-Garcia
 
A
Ambesi-Impiombato
 
A
Hadler
 
M
et al. 
Genetic loss of SH2B3 in acute lymphoblastic leukemia.
Blood
2013
, vol. 
122
 
14
(pg. 
2425
-
2432
)
17
Tzoneva
 
G
Perez-Garcia
 
A
Carpenter
 
Z
et al. 
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
Nat Med
2013
, vol. 
19
 
3
(pg. 
368
-
371
)
18
De Keersmaecker
 
K
Atak
 
ZK
Li
 
N
et al. 
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia.
Nat Genet
2013
, vol. 
45
 
2
(pg. 
186
-
190
)
19
Atak
 
ZK
Gianfelici
 
V
Hulselmans
 
G
et al. 
Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia.
PLoS Genet
2013
, vol. 
9
 
12
pg. 
e1003997
 
20
Papaemmanuil
 
E
Rapado
 
I
Li
 
Y
et al. 
RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.
Nat Genet
2014
, vol. 
46
 
2
(pg. 
116
-
125
)
21
Li
 
Y
Schwab
 
C
Ryan
 
SL
et al. 
Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia.
Nature
2014
, vol. 
508
 
7494
(pg. 
98
-
102
)
22
Roberts
 
KG
Li
 
Y
Payne-Turner
 
D
et al. 
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
N Engl J Med
2014
, vol. 
371
 
11
(pg. 
1005
-
1015
)
23
Trimarchi
 
T
Bilal
 
E
Ntziachristos
 
P
et al. 
Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia.
Cell
2014
, vol. 
158
 
3
(pg. 
593
-
606
)
24
Herranz
 
D
Ambesi-Impiombato
 
A
Palomero
 
T
et al. 
A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.
Nat Med
2014
, vol. 
20
 
10
(pg. 
1130
-
1137
)
25
Mansour
 
MR
Abraham
 
BJ
Anders
 
L
et al. 
Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.
Science
2014
, vol. 
346
 
6215
(pg. 
1373
-
1377
)
26
Harrison
 
CJ
Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia.
Br J Haematol
2009
, vol. 
144
 
2
(pg. 
147
-
156
)
27
Harrison
 
CJ
Moorman
 
AV
Broadfield
 
ZJ
et al. 
Childhood and Adult Leukaemia Working Parties
Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia.
Br J Haematol
2004
, vol. 
125
 
5
(pg. 
552
-
559
)
28
Nachman
 
JB
Heerema
 
NA
Sather
 
H
et al. 
Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia.
Blood
2007
, vol. 
110
 
4
(pg. 
1112
-
1115
)
29
Russell
 
LJ
Capasso
 
M
Vater
 
I
et al. 
Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.
Blood
2009
, vol. 
114
 
13
(pg. 
2688
-
2698
)
30
Den Boer
 
ML
van Slegtenhorst
 
M
De Menezes
 
RX
et al. 
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.
Lancet Oncol
2009
, vol. 
10
 
2
(pg. 
125
-
134
)
31
Cazzaniga
 
G
van Delft
 
FW
Lo Nigro
 
L
et al. 
Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia.
Blood
2011
, vol. 
118
 
20
(pg. 
5559
-
5564
)
32
Safavi
 
S
Forestier
 
E
Golovleva
 
I
et al. 
Loss of chromosomes is the primary event in near-haploid and low-hypodiploid acute lymphoblastic leukemia.
Leukemia
2013
, vol. 
27
 
1
(pg. 
248
-
250
)
33
Anderson
 
K
Lutz
 
C
van Delft
 
FW
et al. 
Genetic variegation of clonal architecture and propagating cells in leukaemia.
Nature
2011
, vol. 
469
 
7330
(pg. 
356
-
361
)
34
Mullighan
 
CG
Phillips
 
LA
Su
 
X
et al. 
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia.
Science
2008
, vol. 
322
 
5906
(pg. 
1377
-
1380
)
35
Ma
 
X
Edmonson
 
M
Yergeau
 
D
et al. 
Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.
Nat Commun
2015
, vol. 
6
 pg. 
6604
 
36
Andersson
 
AK
Ma
 
J
Wang
 
J
et al. 
St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project
The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias.
Nat Genet
2015
, vol. 
47
 
4
(pg. 
330
-
337
)
37
Virely
 
C
Moulin
 
S
Cobaleda
 
C
et al. 
Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia.
Leukemia
2010
, vol. 
24
 
6
(pg. 
1200
-
1204
)
38
Joshi
 
I
Yoshida
 
T
Jena
 
N
et al. 
Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia.
Nat Immunol
2014
, vol. 
15
 
3
(pg. 
294
-
304
)
39
Zhang
 
J
Mullighan
 
CG
Harvey
 
RC
et al. 
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group.
Blood
2011
, vol. 
118
 
11
(pg. 
3080
-
3087
)
40
van der Veer
 
A
Zaliova
 
M
Mottadelli
 
F
et al. 
IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.
Blood
2014
, vol. 
123
 
11
(pg. 
1691
-
1698
)
41
Harvey
 
RC
Mullighan
 
CG
Chen
 
IM
et al. 
Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.
Blood
2010
, vol. 
115
 
26
(pg. 
5312
-
5321
)
42
Yoda
 
A
Yoda
 
Y
Chiaretti
 
S
et al. 
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
Proc Natl Acad Sci USA
2010
, vol. 
107
 
1
(pg. 
252
-
257
)
43
Bercovich
 
D
Ganmore
 
I
Scott
 
LM
et al. 
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down’s syndrome.
Lancet
2008
, vol. 
372
 
9648
(pg. 
1484
-
1492
)
44
Cario
 
G
Zimmermann
 
M
Romey
 
R
et al. 
Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.
Blood
2010
, vol. 
115
 
26
(pg. 
5393
-
5397
)
45
Maude
 
SL
Tasian
 
SK
Vincent
 
T
et al. 
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Blood
2012
, vol. 
120
 
17
(pg. 
3510
-
3518
)
46
Waibel
 
M
Solomon
 
VS
Knight
 
DA
et al. 
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
Cell Reports
2013
, vol. 
5
 
4
(pg. 
1047
-
1059
)
47
Tong
 
W
Zhang
 
J
Lodish
 
HF
Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.
Blood
2005
, vol. 
105
 
12
(pg. 
4604
-
4612
)
48
Shochat
 
C
Tal
 
N
Bandapalli
 
OR
et al. 
Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias.
J Exp Med
2011
, vol. 
208
 
5
(pg. 
901
-
908
)
49
Zenatti
 
PP
Ribeiro
 
D
Li
 
W
et al. 
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.
Nat Genet
2011
, vol. 
43
 
10
(pg. 
932
-
939
)
50
Treanor
 
LM
Zhou
 
S
Janke
 
L
et al. 
Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential.
J Exp Med
2014
, vol. 
211
 
4
(pg. 
701
-
713
)
51
van der Veer
 
A
Waanders
 
E
Pieters
 
R
et al. 
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
Blood
2013
, vol. 
122
 
15
(pg. 
2622
-
2629
)
52
Roberts
 
KG
Pei
 
D
Campana
 
D
et al. 
Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
J Clin Oncol
2014
, vol. 
32
 
27
(pg. 
3012
-
3020
)
53
Schinnerl
 
D
Fortschegger
 
K
Kauer
 
M
et al. 
The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.
Blood
2015
, vol. 
125
 
8
(pg. 
1282
-
1291
)
54
Weston
 
BW
Hayden
 
MA
Roberts
 
KG
et al. 
Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.
J Clin Oncol
2013
, vol. 
31
 
25
(pg. 
e413
-
e416
)
55
Yeoh
 
EJ
Ross
 
ME
Shurtleff
 
SA
et al. 
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.
Cancer Cell
2002
, vol. 
1
 
2
(pg. 
133
-
143
)
56
Mullighan
 
CG
Miller
 
CB
Su
 
X
et al. 
ERG deletions define a novel subtype of B-progenitor acute lymphoblastic leukemia [abstract].
Blood
2007
, vol. 
110
 
11
 
Abstract 691
57
Harvey
 
RC
Mullighan
 
CG
Wang
 
X
et al. 
Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.
Blood
2010
, vol. 
116
 
23
(pg. 
4874
-
4884
)
58
Tomlins
 
SA
Rhodes
 
DR
Perner
 
S
et al. 
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
Science
2005
, vol. 
310
 
5748
(pg. 
644
-
648
)
59
Clappier
 
E
Auclerc
 
MF
Rapion
 
J
et al. 
An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions.
Leukemia
2014
, vol. 
28
 
1
(pg. 
70
-
77
)
60
Moorman
 
AV
Robinson
 
H
Schwab
 
C
et al. 
Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials.
J Clin Oncol
2013
, vol. 
31
 
27
(pg. 
3389
-
3396
)
61
Gutierrez
 
A
Kentsis
 
A
Sanda
 
T
et al. 
The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia.
Blood
2011
, vol. 
118
 
15
(pg. 
4169
-
4173
)
62
Weng
 
AP
Ferrando
 
AA
Lee
 
W
et al. 
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.
Science
2004
, vol. 
306
 
5694
(pg. 
269
-
271
)
63
O’Neil
 
J
Grim
 
J
Strack
 
P
et al. 
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.
J Exp Med
2007
, vol. 
204
 
8
(pg. 
1813
-
1824
)
64
Lahortiga
 
I
De Keersmaecker
 
K
Van Vlierberghe
 
P
et al. 
Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia.
Nat Genet
2007
, vol. 
39
 
5
(pg. 
593
-
595
)
65
Gutierrez
 
A
Sanda
 
T
Grebliunaite
 
R
et al. 
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.
Blood
2009
, vol. 
114
 
3
(pg. 
647
-
650
)
66
Neumann
 
M
Vosberg
 
S
Schlee
 
C
et al. 
Mutational spectrum of adult T-ALL.
Oncotarget
2015
, vol. 
6
 
5
(pg. 
2754
-
2766
)
67
Coustan-Smith
 
E
Mullighan
 
CG
Onciu
 
M
et al. 
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.
Lancet Oncol
2009
, vol. 
10
 
2
(pg. 
147
-
156
)
68
Inukai
 
T
Kiyokawa
 
N
Campana
 
D
et al. 
Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children’s Cancer Study Group Study L99-15.
Br J Haematol
2012
, vol. 
156
 
3
(pg. 
358
-
365
)
69
Patrick
 
K
Wade
 
R
Goulden
 
N
et al. 
Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
Br J Haematol
2014
, vol. 
166
 
3
(pg. 
421
-
424
)
70
Wood
 
B
Winter
 
S
Dunsmore
 
K
et al. 
Patients with early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) have high levels of minimal residual disease (MRD) at the end of induction: a Children's Oncology Group (COG) study [abstract].
Blood
2009
, vol. 
114
 
22
 
Abstract 9
71
Ntziachristos
 
P
Tsirigos
 
A
Van Vlierberghe
 
P
et al. 
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.
Nat Med
2012
, vol. 
18
 
2
(pg. 
298
-
301
)
72
Della Gatta
 
G
Palomero
 
T
Perez-Garcia
 
A
et al. 
Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL.
Nat Med
2012
, vol. 
18
 
3
(pg. 
436
-
440
)
73
Yan
 
L
Ping
 
N
Zhu
 
M
et al. 
Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification.
Haematologica
2012
, vol. 
97
 
11
(pg. 
1708
-
1712
)
74
Maude
 
SL
Dolai
 
S
Delgado-Martin
 
C
et al. 
Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
Blood
2015
, vol. 
125
 
11
(pg. 
1759
-
1767
)
75
Graux
 
C
Cools
 
J
Melotte
 
C
et al. 
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.
Nat Genet
2004
, vol. 
36
 
10
(pg. 
1084
-
1089
)
76
Palomero
 
T
Lim
 
WK
Odom
 
DT
et al. 
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth.
Proc Natl Acad Sci USA
2006
, vol. 
103
 
48
(pg. 
18261
-
18266
)
77
Mar
 
BG
Bullinger
 
LB
McLean
 
KM
et al. 
Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.
Nat Commun
2014
, vol. 
5
 pg. 
3469
 
78
Geng
 
H
Brennan
 
S
Milne
 
TA
et al. 
Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.
Cancer Discov
2012
, vol. 
2
 
11
(pg. 
1004
-
1023
)
79
Figueroa
 
ME
Chen
 
SC
Andersson
 
AK
et al. 
Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia.
J Clin Invest
2013
, vol. 
123
 
7
(pg. 
3099
-
3111
)
80
Jaffe
 
JD
Wang
 
Y
Chan
 
HM
et al. 
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.
Nat Genet
2013
, vol. 
45
 
11
(pg. 
1386
-
1391
)
81
Roderick
 
JE
Tesell
 
J
Shultz
 
LD
et al. 
c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.
Blood
2014
, vol. 
123
 
7
(pg. 
1040
-
1050
)
82
Ntziachristos
 
P
Tsirigos
 
A
Welstead
 
GG
et al. 
Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia.
Nature
2014
, vol. 
514
 
7523
(pg. 
513
-
517
)
83
Hof
 
J
Krentz
 
S
van Schewick
 
C
et al. 
Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.
J Clin Oncol
2011
, vol. 
29
 
23
(pg. 
3185
-
3193
)
84
Meyer
 
JA
Wang
 
J
Hogan
 
LE
et al. 
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.
Nat Genet
2013
, vol. 
45
 
3
(pg. 
290
-
294
)
85
Faham
 
M
Zheng
 
J
Moorhead
 
M
et al. 
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.
Blood
2012
, vol. 
120
 
26
(pg. 
5173
-
5180
)
86
Papaemmanuil
 
E
Hosking
 
FJ
Vijayakrishnan
 
J
et al. 
Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia.
Nat Genet
2009
, vol. 
41
 
9
(pg. 
1006
-
1010
)
87
Treviño
 
LR
Yang
 
W
French
 
D
et al. 
Germline genomic variants associated with childhood acute lymphoblastic leukemia.
Nat Genet
2009
, vol. 
41
 
9
(pg. 
1001
-
1005
)
88
Prasad
 
RB
Hosking
 
FJ
Vijayakrishnan
 
J
et al. 
Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood.
Blood
2010
, vol. 
115
 
9
(pg. 
1765
-
1767
)
89
Xu
 
H
Yang
 
W
Perez-Andreu
 
V
et al. 
Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations.
J Natl Cancer Inst
2013
, vol. 
105
 
10
(pg. 
733
-
742
)
90
Migliorini
 
G
Fiege
 
B
Hosking
 
FJ
et al. 
Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype.
Blood
2013
, vol. 
122
 
19
(pg. 
3298
-
3307
)
91
Yang
 
JJ
Cheng
 
C
Yang
 
W
et al. 
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.
JAMA
2009
, vol. 
301
 
4
(pg. 
393
-
403
)
92
Yang
 
W
Treviño
 
LR
Yang
 
JJ
et al. 
ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence.
Leukemia
2010
, vol. 
24
 
4
(pg. 
894
-
896
)
93
Yang
 
JJ
Cheng
 
C
Devidas
 
M
et al. 
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.
Nat Genet
2011
, vol. 
43
 
3
(pg. 
237
-
241
)
94
Perez-Andreu
 
V
Roberts
 
KG
Harvey
 
RC
et al. 
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse.
Nat Genet
2013
, vol. 
45
 
12
(pg. 
1494
-
1498
)
95
Yang
 
JJ
Cheng
 
C
Devidas
 
M
et al. 
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.
Blood
2012
, vol. 
120
 
20
(pg. 
4197
-
4204
)
96
Akasaka
 
T
Balasas
 
T
Russell
 
LJ
et al. 
Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
Blood
2007
, vol. 
109
 
8
(pg. 
3451
-
3461
)
97
Shah
 
S
Schrader
 
KA
Waanders
 
E
et al. 
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.
Nat Genet
2013
, vol. 
45
 
10
(pg. 
1226
-
1231
)
98
Zhang
 
MY
Churpek
 
JE
Keel
 
SB
et al. 
Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.
Nat Genet
2015
, vol. 
47
 
2
(pg. 
180
-
185
)
99
Noetzli
 
L
Lo
 
RW
Lee-Sherick
 
AB
et al. 
Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia.
Nat Genet
2015
, vol. 
47
 
5
(pg. 
535
-
538
)
100
Pui
 
CH
Carroll
 
WL
Meshinchi
 
S
Arceci
 
RJ
Biology, risk stratification, and therapy of pediatric acute leukemias: an update.
J Clin Oncol
2011
, vol. 
29
 
5
(pg. 
551
-
565
)
101
Pui
 
CH
Campana
 
D
Pei
 
D
et al. 
Treating childhood acute lymphoblastic leukemia without cranial irradiation.
N Engl J Med
2009
, vol. 
360
 
26
(pg. 
2730
-
2741
)
102
Waanders
 
E
van der Velden
 
VH
van der Schoot
 
CE
et al. 
Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia.
Leukemia
2011
, vol. 
25
 
2
(pg. 
254
-
258
)
103
Bhojwani
 
D
Pui
 
CH
Relapsed childhood acute lymphoblastic leukaemia.
Lancet Oncol
2013
, vol. 
14
 
6
(pg. 
e205
-
e217
)
104
Schultz
 
KR
Bowman
 
WP
Aledo
 
A
et al. 
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study.
J Clin Oncol
2009
, vol. 
27
 
31
(pg. 
5175
-
5181
)
105
Biondi
 
A
Schrappe
 
M
De Lorenzo
 
P
et al. 
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.
Lancet Oncol
2012
, vol. 
13
 
9
(pg. 
936
-
945
)
106
Venn
 
NC
van der Velden
 
VH
de Bie
 
M
et al. 
Highly sensitive MRD tests for ALL based on the IKZF1 Δ3-6 microdeletion.
Leukemia
2012
, vol. 
26
 
6
(pg. 
1414
-
1416
)
Sign in via your Institution